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Managing Clinical
Heterogeneity: An Argument for
Benefit-Based Action Limits
The use of reference ranges is well established in medical practice and research. Classi-
cally, a range would be derived from the local healthy population and matched in age,
gender, and other characteristics to the patients under investigation. However, recruiting
suitable controls is problematic and the derivation of the range by excluding 2.5% at
each end of the distribution results in 5% of the values being arbitrarily discarded. Thus,
the traditional reference range is derived using statistical and not clinical principles.
While these considerations are recognized by clinicians, it is often not realized that the
application of whole population derived reference ranges to complex pathologies that
comprise patient subgroups may be problematic. Such subgroups may be identified by
phenotypes including genetic etiology, variations in exposure to a causative agent, and
tumor site. In this review, we provide examples of how subgroups can be identified in
diverse pathologies and how better management can be achieved using evidence-based
action limits rather than reference ranges. We give examples from our clinical experience
of problems arising from using the wrong reference ranges for the clinical situation.
Identifying subgroups will often enable clinicians to derive specific action limits for treat-
ment that will lead to customized management and researchers a route into the study of
complex pathologies. [DOI: 10.1115/1.4039561]
Keywords: laboratory results, heterogeneity, reference ranges, action limits, evidence-
based medicine, lipid lowering therapy, testosterone replacement therapy
Introduction
Determining the concentration of chemicals in body fluids is
commonplace in routine clinical management and research into
disease mechanisms. Thus, in establishing whether an individual
has a disease, the value of an analyte is often compared with those
in a reference range (often mistaken for a healthy or normal range)
derived from the distribution of the analyte in an assumed healthy
population. Such distributions are often Gaussian (e.g., serum glu-
cose) though asymmetrical distributions are observed (e.g., serum
bilirubin). In a Gaussian distribution, 95% of the samples will be
symmetrically distributed around the mean and included in the
formula, mean 62 SD (Fig. 1). Rather arbitrarily, this formula
describes a reference range. Importantly, 2.5% of the samples at
the high and low ends have been ignored. Thus, the classic refer-
ence range is based on two assumptions: first, the selected individ-
uals comprise a reasonable comparison group for patients under
investigation for a particular pathology, and second, 5% of these
apparently healthy subjects tested have an analyte level out with
the reference range.
While reference ranges are widely used and are usually helpful,
their use in clinical medicine without consideration of relevant fac-
tors such as clinical presentation and medication can be problematic.
For example, the reference range for cortisol (>550nmol/l) was
removed from one Hospital laboratory’s reports following the death
of a patient, admitted in a semi-conscious state exhibiting a purpuric
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rash and a cortisol level just inside the reference range (unpub-
lished). Because this result was initially considered “normal” (it
should have been substantially higher due to a stress response), the
correct diagnosis was not made sufficiently early.
Clearly, clinical presentations are heterogeneous and the above
sad example shows that interpretation of an analyte concentration
must take into account the clinical status (the degree of stress in
the above case could be viewed as presentation heterogeneity).
Accordingly, we now discuss the usefulness of reference ranges in
patients with complex, multifactorial pathologies. In particular,
we consider examples of subgroups that comprise the combination
of patients with particular diseases. We give examples of clinical
conditions in which reference ranges have been or are in the pro-
cess of being replaced by action limits, such decisions being based
on basic science and intervention studies.
Disease Viewed as a Homogeneous Entity
Figure 2 shows a simple pathway with causative factor(s) lead-
ing to a disease, perceived as homogeneous. It is diagnosed via
clinical presentation(s) and further investigations. Often guide-
lines seeking simplicity adopt this format with heterogeneity
being ignored. This approach leads to relatively easy diagnosis
and treatment with minimal cost. However, such simplicity may
compromise understanding of the disease process, optimization of
treatment, and slow further research.
A good example of this approach is the United Kingdom
National Institute for Health and Care Excellence (NICE) guide-
line for the management of type 2 diabetes (T2DM),3 which
appears to consider this disease as a single pathology with no
allowance for different causative factors. Therapeutic manage-
ment is based on glycemic control, hypertension, and cardiovascu-
lar disease (CVD) risk and is not tailored to the major underlying
causative factors of beta cell dysfunction and insulin resistance.
Guidelines are largely driven by evidence-based medicine, prin-
cipally primary end points of randomized controlled trials (RCT)
and cost-effectiveness, often measured as quality adjusted Life
Years if benefit has been demonstrated. Thus, subgroups will only
be considered if the RCT inclusion criteria restrict the patient
cohort to one (or more) identified subgroup. This is evident in trials
investigating the benefits of lipid lowering in differing clinical pre-
sentations (which can be considered subgroups). The NICE guide-
lines (CG1814), recommending risk assessment and reduction of
adult CVD including lipid modification, consider CVD (a compos-
ite of coronary heart disease (CHD) and stroke) as a single pathol-
ogy with no specific causative factors. However, where therapeutic
management is considered for CVD risk reduction, subgroups such
as patients with T2DM and those requiring primary prevention or
secondary prevention are considered separately, because of the
inclusion criteria of RCT. Interestingly, separate guidelines (CG
715) have been designed for familial hypercholesterolemia (FH),
but no other etiology or classification such as the metabolic syn-
drome (MetS). Although subgroup analyses of the trials show that
patients with the MetS (up to 33% of patients in the five main
fibrate trials) do benefit from fibrate therapy [1], the NICE guide-
lines do not recommend these therapeutic agents. Thus, it is clear
that most guidelines are rigidly based on the populations included
in RCTs. Often, different subgroups are grouped together; this
broad-brush methodology could lead to a subgroup benefiting
greatly from an intervention not being identified due to dilution of
the outcome results with subgroups that do not benefit.
The above argument demonstrates the importance of subgroups
based on etiology and/or clinical presentations being identified.
This leads to a more complex network of phenotypes grouped
together as a single pathology. Figure 3 demonstrates potential
aspects of this complexity. It is clear that over time, the guidelines
dealing with lipid lowering have partially moved toward Fig. 3
with FH (etiology) and primary/secondary CVD (clinical presen-
tation) prevention having separate management strategies.
Identification of subgroups can be based on relatively simple
presentational phenotypes as well as more complex genetic sus-
ceptibility markers. For example, in patients with basal cell carci-
noma (BCC), we identified different tumor presentation
phenotypes and some of their associated susceptibility and modi-
fying factors [2–5]. Thus, Fig. 4 shows putative subgroups we
identified in patients with at least one BCC. While many patients
develop only one tumor, others were found to have “clusters” of
multiple lesions over similar follow-up periods. Tumor site is a
further aspect of heterogeneity. We speculated that, and obtained
evidence for the concept that, each subgroup may describe differ-
ing disease causation pathways, host susceptibility factors, envi-
ronmental exposures, prognosis, and possibly treatment options.
Identification of these subgroups enabled us to present a hypo-
thetical model incorporating susceptibility factors and a variable
disease risk threshold for BCC [3]. Figure 5 demonstrates how
age-related changes in immune surveillance may influence the
numbers of BCC; single tumors or clusters (presentation pheno-
types observed). Reduced immune surveillance leads to crossing
the BCC threshold and is associated with the release of pre-
existing microtumors and a visible, initial BCC. Recovery of
immune surveillance can also influence phenotype and outcome
by immune surveillance rising above the threshold. Continuous,
and hence, more severe loss of surveillance with the patient
remaining below the threshold leads to a higher rate of BCC
development often seen as clusters. The threshold level is not con-
sidered as absolute, but a variable level is specific for each indi-
vidual and is influenced by other risk factors. This generic model
could be applied to other mechanisms and presentation subgroups.
The above model can be used to consider the relationship
between clinical heterogeneity and risk factors in any chronic
pathology. Thus, Horton et al. in 2009 published a similar scheme
showing subgroups, risk factors, and disease thresholds for CHD
[6]. Subgroups recognized were FH (both homozygous and heter-
ozygous) and “loss of function” PCSK9 states. The improved
prognosis associated with loss of function PCSK9 mutation sub-
group has given rise to PCSK9 inhibitors and therapeutic agents
in which early trials show encouraging results.
Action Limits Replacing Reference Ranges in Patient
Management
Since there will sometimes be profoundly different mechanisms
determining causation and prognosis in subgroups, the use of a
universal reference range for an analyte of interest may be inap-
propriate. The use of subgroup specific action limits may be a bet-
ter approach. Evidence based on RCT’s has led to action limits
Fig. 1 An illustration of a normal (Gaussian) distribution and
derived reference range
3https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-
management-pdf-1837338615493
4https://www.nice.org.uk/guidance/cg181 5https://www.nice.org.uk/guidance/cg71
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replacing reference ranges in guidelines, regardless of whether a
pathology is considered homogeneous (Fig. 2) or heterogeneous
(Fig. 3). This move driven by clinical research shows the need for
researchers to allow for heterogeneity in the design of trials.
We now consider two clinical areas at differing stages of accep-
tance of use of action limits. First, how low density lipoprotein
cholesterol (LDL-c) action limits replaced reference ranges in
lipid lowering, and second, male hypogonadism (HG) where the
evidence base is less mature and reference ranges are still quoted
and used when it may be more advisable to move to action limits.
Low Density Lipoprotein-Cholesterol and Cardiovascu-
lar Disease
Atherosclerotic obstruction of arteries by plaque formation
leading to CVD such as myocardial infarction and stroke is one of
the commonest causes of mortality in developed countries.
Though the rate has been falling, CVD is still a leading cause of
death in the United Kingdom [7] (Office for National Statistics,
Deaths registered in England and Wales 2015)6. Various CVD
risk factors have been identified. In 1948, the Framingham Heart
Study followed 5209 adults aged 30–62 years to identify contrib-
uting factors associated with CVD [8]. Every 2 years, participants
provided a detailed medical history and underwent a physical
examination and laboratory testing. Since the initial phase, the
study has expanded with two further generations being recruited.
Age, male gender, elevated blood pressure, diabetes, smoking,
total cholesterol (TC), and high density lipoprotein cholesterol
ratio are associated with CHD, and accordingly, these factors
were built into a primary prevention algorithm to estimate CVD
risk in patients without established CVD. Association between lip-
ids and CVD does not imply causation and it required intervention
trials where lipid lowering (with more than one agent working via
different pathways) led to a reduction in CVD risk before a causa-
tive role was established with a high degree of certainty.
The association between cholesterol and atherosclerosis led to
the coronary primary prevention trial which demonstrated reduction
of CVD following cholesterol reduction with cholestyramine [9].
This gave rise to the LDL hypothesis; LDL-c being a causative fac-
tor of atherosclerosis. Since the Scandinavian Simvastatin Survival
Study (4S) in 1994, statins provide the mainstay of lipid lowering
treatments [10]. Statins block hepatic cholesterol synthesis leading
to upregulation of LDL receptors and increase in LDL particle
uptake, thereby lowering serum LDL-c and TC. The evidence from
4S prompted us to move away from TC reference ranges and adopt
an action limit of below 5.2mmol/l for the coronary cholesterol
clinic treating secondary prevention patients in the Manor Hospital,
Walsall [11]. The significant CVD risk reduction observed in 4S
was replicated in many other intervention trial studies [12–18].
Following these intervention trials, the Joint British Societies
(JBS) and European Atherosclerosis Society recommended sec-
ondary prevention treatment targets of TC< 5mmol/l and/or
LDL-c< 3mmol/l in 1998 [12,18]. More recent studies clearly
demonstrate that “lower is better” regards TC and LDL-c levels
[14,17,19]. The LDL hypothesis was given a boost by the SHARP
[20] and IMPROVE-IT [21] studies where addition of ezetimibe,
a LDL-c lowering agent with a mechanism of action different
from statins, was demonstrated to reduce CVD risk as predicted
by the LDL-c reduction seen in various statin trials. These inter-
vention trials formed the basis of the JBS 2 guidelines [22]. They
recommended treating with new optimal targets of TC <4mmol/l
and/or LDL-c <2mmol/l with the previous targets, TC <5mmol/l
Fig. 2 Management of pathology viewed as a homogeneous entity
Fig. 3 Management of a pathology as a heterogeneous entity
6https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/
deaths/bulletins/deathsregisteredinenglandandwalesseriesdr/2015
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and LDL-c <3mmol/l, now viewed as minimal targets which
were now adopted as lipid targets in the quality and outcomes
framework, a primary care incentive scheme in the United King-
dom [23]. The revamped JBS 3 guidelines published in 2014 sug-
gest that non-high density lipoprotein–cholesterol target of
<2.5mmol/l, considered equivalent to a LDL-c< 1.8mmol/l in
secondary prevention and lifetime risk reduction as opposed to
absolute risk reduction in primary prevention should also be con-
sidered [24].
Simplified versions of the Framingham risk algorithms were
created for routine CVD risk estimation such as the Sheffield
Tables in the UK [25]. Currently, the NICE guidelines (CG 181)4
advise primary care to use the QRISK2 risk calculator instead of
the Framingham risk score. QRISK is a prediction system, similar
Fig. 4 Susceptibility, environmental and modifying factors leading to various BCC subgroups (12n) defined
by presentation, each with specific causative mechanisms (12n)
Fig. 5 Scheme depicting how immune surveillance could determine BCC presentation
phenotypes
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to the Framingham risk score, which uses a combination of tradi-
tional risk factors (age, blood pressure, and cholesterol) and other
factors (including family history, body mass index, and ethnicity).
It has the advantage of being derived from data obtained from
patients in the UK.
These algorithms estimating risk are not ideal in high risk indi-
viduals such as those with established CVD (secondary preven-
tion) and FH. This indicates the presence of functional subgroups
determined by risk and not etiology; greater benefit may be seen
with lipid lowering treatment in patients at higher risk. Thus,
action limits for lipid lowering treatment can differ. Heterozygous
FH is the commonest single gene disease in the UK (1:500) [26].
If left untreated, around 50% of men and 30% of women with FH
will develop CVD by the age of 50 and 60 years, respectively
[26]. Most CVD risk factors are modifiable and treatable. These
include high blood pressure, lipids, obesity, diabetes, physical
activity levels, and tobacco usage. Regarding primary prevention,
it is recommended that patients have their probability of CVD
estimated via a risk calculator (QRISK 2) and statin treatment
offered based on the underlying 10-year probability (NICE CG
181).4 The 10-year CVD probability treatment threshold has
decreased from 30% [27] to 20% [22] and now to 10% [24]. Once
again, population-based reference ranges have been superseded by
more complex indices. Different approaches toward primary and
secondary prevention are due to the inherent risk of the population
being considered. Functional subgroups demonstrating varying
therapeutic benefits have also been seen in CVD prevention.
There appears to be considerable residual CVD risk following
statin treatment especially in cases with the atherogenic lipopro-
tein phenotype, the dyslipidemia characterizing the MetS [28].
Thus, in patients with MetS, it may be unwise to consider LDL-c
in the same way as in other patients. Thus, a different approach to
hyperlipidemia may yield benefits in patients with the MetS. The
MetS in our opinion is poorly classified with defining variables
dichotomized and many associated factors omitted [29]. Thus, we
would consider that heterogeneity exists even within the MetS,
which itself must be distinguished from other dyslipidemic pat-
terns. Meta-analysis has suggested that fibric acid derivatives
should only be used in patients demonstrating the atherogenic lip-
oprotein phenotype [1,30]. Thus, optimal management in dyslipi-
demia requires recognition of subgroups based on etiology,
evidence, and underlying risk levels and customizing the treat-
ment. This leads to a more sophisticated disease model with a req-
uisite for greater knowledge and skill on the part of health care
professionals and researchers.
Testosterone, Late Onset Hypogonadism and
Testosterone Replacement Therapy
Late onset HG in men, as opposed to primary (testicular pathol-
ogy) and secondary (pituitary/hypothalamic pathology), is defined
as a combination of sexual symptoms and serum total testosterone
levels <12 nmol/l [31]. Age-related late onset HG is seen in
6–12% of men and affects metabolic parameters associated with
ill health and morbidity/mortality risk in adult men [32].
The European Male Aging study of 2599 men aged 40–79 years
(T2DM: 7%, follow up 4 years) showed hypogonadal symptoms
and total testosterone levels< 8 nmol/l, independently and in com-
bination predicted overall and CVD mortality [33]. However, cau-
sality of the association could only be suggested if testosterone
replacement therapy (TRT) led to risk reduction. Shores et al.
investigated the effects of TRT in 1031 males aged over 40 years
with total testosterone levels  8.7 nmol/l [34]. TRT in 398 of
these men halved mortality (treated men: 10.3%, mean follow-up:
42.8 months; untreated men: 20.7%, mean follow-up: 38 months).
When the patient cohort was stratified, the mortality reduction
was significant in those with T2DM (HR:0.44, CI:0.23-0.84) but
not in non-T2DM men (HR:0.72, CI:0.46-1.13). Both the associa-
tion between late onset HG and mortality and mortality reduction
following TRT in men with T2DM were confirmed by
Muraleedaran et al. in 581 men with T2DM over 6 years follow-
up [35]. The patient cohort was stratified by total testosterone lev-
els of 10.4 nmol/l; 343 patients were classified as normal and 238
patients classified as having a low testosterone. In the low testos-
terone group, 174 untreated patients demonstrated significantly
higher mortality compared to men on TRT after adjustment for
covariates. We obtained similar results in 857 men with T2DM
and late onset HG, using a total testosterone cut-off of 12.0 nmol/l
or a free testosterone of 0.25 nmol/l [36,37].
While these studies do not allow definition of precise, cut-off
values for testosterone that are associated with increased mortality
in either diabetic or nondiabetic subjects, they do raise issues
regarding what level should be considered as normal or healthy.
Thus, laboratory testosterone measurement is recommended in men
with HG and obesity [32]. There is a wide variation in reference
ranges for total testosterone. The reference range of the Mayo Med-
ical Laboratories for total testosterone is 8.3–33.0 nmol/l
(240–950ng/ml)7 in adult men and is not in line with the increasing
benefits seen in some of the above cited longitudinal studies
[34–37]. These studies suggest total testosterone thresholds should
be< 8.7 nmol/l (250.9 ng/dl) in nondiabetic [34] and <10.4 nmol/l
(300.0 ng/dl) [35] or even 12nmol/l [36,37] in men with T2DM,
when considering TRT. An understanding of the meaning of refer-
ence ranges and current evidence will enable a change toward
action limits for testosterone as seen in lipidology [38].
Is It Time to Move Away From Population-Based
Reference Ranges?
These two examples show areas with mature data (LDL-c) and
accumulating data (testosterone) that allow derivation of action
limits. Lipid lowering treatment is based on either action limits or
overall CVD risk assessment. To obtain optimum benefit from
therapy, clinicians need an understanding of disease mechanisms,
up to date evidence from trials and other data such as meta-
analyses as well as the drug pharmacology. Importantly in both
clinical practice and research, CVD and most other diseases
should be viewed as an end clinical state reached via various path-
ways with different risk factors. Thus, the population-based LDL-
c reference range has been ignored by clinicians and researchers,
although they are found in laboratory reports. Unlike in the case
of testosterone, there are sufficient guidelines over the past 20
years for clinicians not to be influenced by the LDL-c reference
range. This is unfortunately not the case with testosterone where
evidence of benefit following TRT has not been widely dissemi-
nated. The lesson from lipid lowering is that considerable time is
required to erode skepticism.
It is likely that heterogeneity exists within late onset HG. This
can be, at least initially, identified by stratifying disease presenta-
tion patterns and causative factors. Following this, action limits for
treatment will have to be periodically refined based on evidence.
Case History
The potential problem resulting from unconsidered use of a lab-
oratory reference range is exemplified by the case of a middle-
aged male who lead an active and healthy lifestyle (unpublished).
He gave a 12-month history of worsening fatigue, frequent hot
flushes, loss of libido, erectile dysfunction, depression, and loss of
mental focus, which are common symptoms of HG. He requested
to measure the testosterone levels and his morning total testoster-
one level was found to be 9.9 nmol/l. His request for TRT was
refused as the total testosterone level was within the local labora-
tory reference range of 4–32 nmol/l. Desperation led to the patient
sourcing testosterone enanthate and self-injecting every 10 days
using a dose higher than those conventionally used for testoster-
one undecanoate. This treatment resulted in markedly improved
7http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/
83686
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HG symptoms. Since then, he has contacted a specialist and is
now receiving testosterone undecanoate administered under pro-
fessional care. The challenge might be the achievement of long-
term maintenance of testosterone levels above 15 nmol/l as recom-
mended by expert guidelines [38], if primary care follow-up is
dependent once more on laboratory reference ranges. This real
life case demonstrates the danger of using reference ranges with-
out consideration of clinical presentation(s) though we recognize
that a single anecdotal example cannot determine clinical policy.
However, there is already ample evidence showing that a total tes-
tosterone level below 15 nmol/l can be associated with symptoms
[39] and that TRT in men with HG and total testosterone
<12 nmol/l leads to clinical improvement of symptoms [40,41].
Conclusion
Clinical heterogeneity is a facet of the developing interest in
personalized medicine. In our experience, research scientists (out-
side clinical biochemists) have a limited understanding of how a
reference range is derived and used and of clinical heterogeneity.
Further, perhaps surprisingly, many medical undergraduate
courses include little formal training on how to use chemical
pathology services and reference ranges that are often viewed by
newly qualified doctors as absolute markers of health or disease.
Experienced clinicians of course recognize disease heterogeneity
in their patients. Interaction between such clinicians and clinical
scientists and researchers should lead to better exchange of scien-
tific and medical principles and use of research data. The benefits
of this approach can be seen in various NICE guidelines for pri-
mary and secondary prevention of CVD as well as familial hyper-
cholesterolemia. In our view, the MetS and the pathologies
associated with it including late onset HG are clinical conditions
that would benefit from this approach.
In conclusion, while we believe the identification and study of
patient subgroups is important, we recognize that choosing the
characteristic(s) used to classify subgroups is critical. Clearly,
overenthusiastic use of multiple characteristics will result in rela-
tively large numbers of subgroups comprising relatively few sub-
jects making statistical analysis problematic. This problem will be
compounded by using characteristics that are difficult to quantify
precisely. Thus, the use of genetic factors (e.g., allelic variants)
may allow more robust analysis than phenotypes such as skin
type. This issue is of particular importance in the design of RCTs;
inclusion criteria for the trial cohort should be based on a particu-
lar subgroup with a relevant outcome as primary outcome.
Issues of assay accuracy and precision also influence the reli-
ability of clinical action limits. Thus, selecting an action limit for
an analyte should reflect the coefficient of variation of the assay
used to determine its concentration. Further, as different analytical
methodologies may be used by laboratories, quality assurance
schemes should be used to ensure that particular action limits are
standardized.
Summary
It is evident that clinical heterogeneity exists in all pathologies
and it seems reasonable to speculate that this may reflect different
causative mechanisms and prognoses. We believe it would be
helpful if intervention trials paid more attention to identifying
possible subgroups on the basis of etiology or clinical presentation
thereby allowing a complete understanding of the benefits of ther-
apy (including customized therapy), and better options for
researchers to unravel causative and prognostic mechanisms.
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